1030377-25-3 Usage
General Description
1-Benzyl 4-(2-methyl-2-propanyl) (5R)-5-methyl-1,4-diazepane-1,4-dicarboxylate is a complex chemical compound. Its molecular properties have yet to be thoroughly researched, indicating that its exact composition, behavior, and potential applications are not concretely determined. As classified by IUPAC, it contains diazepane as its core chemical structure, which characterizes a seven-membered ring containing two nitrogen atoms. These diazepane-related structures are prevalent in many medicinal chemistry studies due to their potential applications in drug development. Also, in this compound, 5R represents a specific arrangement of atoms, suggesting that it is chiral—a property that is significant in many pharmaceuticals. The benzyl and methyl groups in the compound can influence its reactivity and polarity. Nonetheless, more investigation is necessary to ascertain the specific characteristics and potential uses of this particular chemical compound.
Check Digit Verification of cas no
The CAS Registry Mumber 1030377-25-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,0,3,7 and 7 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1030377-25:
(9*1)+(8*0)+(7*3)+(6*0)+(5*3)+(4*7)+(3*7)+(2*2)+(1*5)=103
103 % 10 = 3
So 1030377-25-3 is a valid CAS Registry Number.
1030377-25-3Relevant articles and documents
A facile electrochemical synthesis of suvorexant
Ghoshal, Tanay,Patel, Tarun M.,Kotturi, Sharadsrikar
, (2021)
A facile, scalable electrochemical method to prepare Suvorexant has been developed. Two different electrochemical routes explored. The route with the high yield and less step taken forward.
Substituted diazepan orexin receptor antagonists
-
Page/Page column 15, (2008/12/05)
The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.